HK1154505A1 - Process to minimize polymorphism - Google Patents

Process to minimize polymorphism

Info

Publication number
HK1154505A1
HK1154505A1 HK11108783.1A HK11108783A HK1154505A1 HK 1154505 A1 HK1154505 A1 HK 1154505A1 HK 11108783 A HK11108783 A HK 11108783A HK 1154505 A1 HK1154505 A1 HK 1154505A1
Authority
HK
Hong Kong
Prior art keywords
polymorphism
minimize
minimize polymorphism
Prior art date
Application number
HK11108783.1A
Other languages
English (en)
Chinese (zh)
Inventor
Simon A M Howes
Rosie Mclaughlin
Andrew Jordan
Wei Tian
Original Assignee
Rp Scherer Technologies Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rp Scherer Technologies Llc filed Critical Rp Scherer Technologies Llc
Publication of HK1154505A1 publication Critical patent/HK1154505A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/55171,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK11108783.1A 2008-02-28 2011-08-19 Process to minimize polymorphism HK1154505A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3229808P 2008-02-28 2008-02-28
PCT/US2009/035276 WO2009108775A2 (en) 2008-02-28 2009-02-26 Process to minimize polymorphism

Publications (1)

Publication Number Publication Date
HK1154505A1 true HK1154505A1 (en) 2012-04-27

Family

ID=41016708

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108783.1A HK1154505A1 (en) 2008-02-28 2011-08-19 Process to minimize polymorphism

Country Status (19)

Country Link
US (1) US20090226522A1 (pt)
EP (1) EP2247284B1 (pt)
JP (2) JP5547096B2 (pt)
KR (1) KR101473419B1 (pt)
CN (2) CN103751091B (pt)
AR (1) AR072245A1 (pt)
AU (1) AU2009219292B2 (pt)
BR (1) BRPI0908539B8 (pt)
CA (1) CA2716901C (pt)
DK (1) DK2247284T3 (pt)
ES (1) ES2633928T3 (pt)
HK (1) HK1154505A1 (pt)
IL (2) IL207824A (pt)
MX (1) MX2010009493A (pt)
MY (1) MY173867A (pt)
NZ (1) NZ587611A (pt)
RU (1) RU2010139643A (pt)
WO (1) WO2009108775A2 (pt)
ZA (1) ZA201006421B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX347101B (es) * 2010-10-08 2017-04-12 Scherer Technologies Llc R P Forma de dosis de disolucion rapida de vacuna oral que usa almidon.
WO2016138357A1 (en) 2015-02-27 2016-09-01 Kindred Biosciences, Inc. Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物
US11839604B2 (en) 2016-12-31 2023-12-12 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
CN112888431B (zh) 2018-06-27 2022-06-03 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
CN109010295A (zh) * 2018-08-29 2018-12-18 北京兴源联合医药科技有限公司 一种左甲状腺素钠冻干口腔崩解片
CN109316452B (zh) * 2018-09-07 2021-07-30 北京兴源联合医药科技有限公司 一种硫酸氢氯吡格雷冻干口腔崩解片
SG11202108690YA (en) 2019-02-22 2021-09-29 Catalent Uk Swindon Zydis Ltd Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen
ES2964108T3 (es) 2019-02-22 2024-04-04 Catalent Uk Swindon Zydis Ltd Minimización de la aglomeración de material de recubrimiento de partículas farmacológicas durante el almacenamiento para estabilizar los tiempos de disgregación de los productos farmacéuticos
CA3145388A1 (en) 2019-07-19 2021-01-28 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN115968281A (zh) * 2020-07-31 2023-04-14 康特伦英国斯温顿捷迪斯有限公司 包含经包衣api的药物组合物
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
DD289468B5 (de) 1989-11-07 1994-02-10 Dresden Arzneimittel Arzneimitteltechnologisches verfahren zur herstellung einer alprazolam-arzneiform
CA2020018A1 (en) * 1990-06-27 1991-12-28 Don L. Simmons Method and composition for treating the migraine complex
JP3069458B2 (ja) * 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
DE69429119T2 (de) * 1993-07-09 2002-07-18 Scherer Corp R P Verfahren zur herstellung von gefriergetrockneten arzneistoffdosierungsformen
US5457895A (en) * 1993-10-01 1995-10-17 R. P. Scherer Corporation Method of identifying freeze-dried dosage forms
CZ289649B6 (cs) * 1994-07-22 2002-03-13 Krka, Tovarna Zdravil. P.O. Pevné lékové formy se spolehlivým uvolňováním aktivní sloľky alprazolamu a způsob jejich přípravy
ES2217410T3 (es) * 1996-04-16 2004-11-01 Novartis Consumer Health S.A. Forma de dosificacion oral de rapida desintegracion.
US5958453A (en) * 1996-10-31 1999-09-28 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with improved buccal disintegrability and/or dissolubility
US5869098A (en) * 1997-08-20 1999-02-09 Fuisz Technologies Ltd. Fast-dissolving comestible units formed under high-speed/high-pressure conditions
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
DE69828310T2 (de) * 1997-12-26 2005-05-25 Warner-Lambert Co. Llc Gelatinzusammensetzungen
GB9908014D0 (en) 1999-04-08 1999-06-02 Scherer Corp R P Pharmaceutical compositions
EP1401503B1 (en) * 2001-06-22 2007-05-09 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug and a solubility-enhancing polymer
US6509040B1 (en) * 2001-06-22 2003-01-21 R.P. Scherer Corporation Fast dispersing dosage forms essentially free of mammalian gelatin
US7972621B2 (en) * 2004-06-03 2011-07-05 R.P. Scherer Technologies, Llc Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US7855196B2 (en) * 2005-08-22 2010-12-21 Pierre Mainville Composition comprising a benzodiazepine agonist and a benzodiazepine antagonist
US20070105788A1 (en) * 2005-11-09 2007-05-10 Serena Mraz-Gernhard Azithromycin for treatment of granulomatous rosacea
GB0714223D0 (en) * 2007-07-20 2007-08-29 Fujifilm Mfg Europe Bv Preparation of fine particles

Also Published As

Publication number Publication date
RU2010139643A (ru) 2012-04-10
CA2716901A1 (en) 2009-09-03
WO2009108775A3 (en) 2009-12-03
CN102036655A (zh) 2011-04-27
ZA201006421B (en) 2011-05-25
IL252713A0 (en) 2017-08-31
EP2247284A2 (en) 2010-11-10
WO2009108775A2 (en) 2009-09-03
NZ587611A (en) 2012-07-27
IL207824A (en) 2017-11-30
EP2247284B1 (en) 2017-04-19
CA2716901C (en) 2018-07-03
JP5547096B2 (ja) 2014-07-09
JP2014062119A (ja) 2014-04-10
ES2633928T3 (es) 2017-09-26
BRPI0908539B8 (pt) 2021-05-25
KR101473419B1 (ko) 2014-12-16
MX2010009493A (es) 2010-12-20
US20090226522A1 (en) 2009-09-10
EP2247284A4 (en) 2013-10-02
AU2009219292A1 (en) 2009-09-03
IL207824A0 (en) 2010-12-30
DK2247284T3 (en) 2017-07-31
CN103751091B (zh) 2017-08-25
AU2009219292B2 (en) 2014-02-27
AR072245A1 (es) 2010-08-18
KR20100123740A (ko) 2010-11-24
CN102036655B (zh) 2013-11-20
BRPI0908539B1 (pt) 2020-12-08
JP2011513324A (ja) 2011-04-28
CN103751091A (zh) 2014-04-30
MY173867A (en) 2020-02-25

Similar Documents

Publication Publication Date Title
IL252713A0 (en) A process for reducing multiforms
GB0806422D0 (en) Process
GB0806419D0 (en) Process
GB0808836D0 (en) Process
GB0814519D0 (en) Process
GB0812742D0 (en) Process
GB0814053D0 (en) Process
GB0801209D0 (en) Process
GB0803669D0 (en) Process
GB0801580D0 (en) Process
GB0813598D0 (en) Process
GB0813433D0 (en) Process
GB0800875D0 (en) Process
GB0812400D0 (en) Process
GB0811851D0 (en) Process
GB0807161D0 (en) Process
GB0803960D0 (en) Process
GB0808764D0 (en) Process
GB0808357D0 (en) Process
GB0812919D0 (en) Process
GB0803663D0 (en) Process
GB0812098D0 (en) Process
GB0808359D0 (en) Process
GB0822880D0 (en) Novel process
GB0815882D0 (en) Novel process